MDT

86.56

+0.83%↑

113.95

+1.74%↑

VEEV

175.31

+0.07%↑

HQY

83.18

+1.87%↑

CSBR

5.69

+2.34%↑

MDT

86.56

+0.83%↑

113.95

+1.74%↑

VEEV

175.31

+0.07%↑

HQY

83.18

+1.87%↑

CSBR

5.69

+2.34%↑

MDT

86.56

+0.83%↑

113.95

+1.74%↑

VEEV

175.31

+0.07%↑

HQY

83.18

+1.87%↑

CSBR

5.69

+2.34%↑

MDT

86.56

+0.83%↑

113.95

+1.74%↑

VEEV

175.31

+0.07%↑

HQY

83.18

+1.87%↑

CSBR

5.69

+2.34%↑

MDT

86.56

+0.83%↑

113.95

+1.74%↑

VEEV

175.31

+0.07%↑

HQY

83.18

+1.87%↑

CSBR

5.69

+2.34%↑

Home・Akciju saraksts・Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals Inc

Slēgts

SektorsVeselības aprūpe

74.98 3.52

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

72.62

Max

75.82

Galvenie mērījumi
By Trading Economics
Ienākumi	-100M -229M
Pārdošana	46M 203M
Peļņas marža	-112.808
Darbinieki	1,402
EBITDA	4.7B 4.6B

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+34.02% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 29. apr.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-2B 12B
Iepriekšējā atvēršanas cena	71.46
Iepriekšējā slēgšanas cena	74.98

Ziņu noskaņojums

By Acuity

50%

169 / 349 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Neutral Evidence

29.78 / 33.645 Atbalsts un pretestība

Ionis Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 30. marts 23:15 UTC

Galvenie ziņu notikumi

U.K. Shoppers Paid a Little More This Month But Worse May yet Lie Ahead

2026. g. 30. marts 22:36 UTC

Galvenie ziņu notikumi

Australian Government Rules Out Boots on the Ground in the Middle East

2026. g. 30. marts 22:13 UTC

Iegādes, apvienošanās, pārņemšana

Sun Life Financial Agrees to Buy Bell Partners for $350 Million

2026. g. 30. marts 21:00 UTC

Peļņas

Aktis Oncology Gets FDA Clearance for Phase 1 Billion Trial of Tumor Treatment

2026. g. 30. marts 20:15 UTC

Galvenie ziņu notikumi

Fed's Williams: Middle-East Developments Have Added Significant Economic Uncertainty

2026. g. 30. marts 23:40 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 30. marts 23:40 UTC

Tirgus saruna

Nikkei May Decline on Higher Energy Cost Concerns -- Market Talk

2026. g. 30. marts 23:36 UTC

Tirgus saruna

Gold Edges Lower Amid Divergent Signals on U.S.-Iran Talks -- Market Talk

2026. g. 30. marts 23:12 UTC

Tirgus saruna

Alcoa Earnings Outlook Boosted by Market Disruptions -- Market Talk

2026. g. 30. marts 22:49 UTC

Tirgus saruna

Fed's Williams: Core Inflation Forecast Is Little Changed -- Market Talk

2026. g. 30. marts 22:44 UTC

Tirgus saruna

Fed's Williams: Risks to Both Sides of Dual Mandate Higher -- Market Talk

2026. g. 30. marts 22:43 UTC

Tirgus saruna

Fed's Williams Says Focus Is on Inflation Expectations Being Well Anchored -- Market Talk

2026. g. 30. marts 22:42 UTC

Tirgus saruna

South32 Should Go for Growth, Says New Bull -- Market Talk

2026. g. 30. marts 22:18 UTC

Tirgus saruna

Paragon Care's Chances of Using Levy to Pass on Higher Costs `Close to Zero' -- Market Talk

2026. g. 30. marts 22:05 UTC

Tirgus saruna

Northern Star's New Bull Argues Case for Asset Sales -- Market Talk

2026. g. 30. marts 21:58 UTC

Iegādes, apvienošanās, pārņemšana

Sun Life Financial Agrees to Buy Bell Partners for $350M

2026. g. 30. marts 21:39 UTC

Iegādes, apvienošanās, pārņemšana

Sun Life Sees 1Q Charge to Net of C$236M From BGO, Crescent Deals

2026. g. 30. marts 21:38 UTC

Iegādes, apvienošanās, pārņemšana

Sun Life: Completes Remaining Equity Interest Purchases of BGO, Crescent Capital

2026. g. 30. marts 21:36 UTC

Iegādes, apvienošanās, pārņemšana

Sun Life to Buy Fully Bell Partners for $350M >SLF.T

2026. g. 30. marts 21:33 UTC

Iegādes, apvienošanās, pārņemšana

Unilever Shareholders Expected to Own Two-Thirds of New Food Entity, Sources Say -- WSJ

2026. g. 30. marts 21:33 UTC

Iegādes, apvienošanās, pārņemšana

Unilever Nears Deal to Create $60 Billion Food Giant With McCormick -- WSJ

2026. g. 30. marts 21:33 UTC

Iegādes, apvienošanās, pārņemšana

Deal Could Be Announced As Soon As Tuesday, Sources Say -- WSJ

2026. g. 30. marts 21:33 UTC

Iegādes, apvienošanās, pārņemšana

Unilever Nears Cash-and-Stock Deal to Combine Food Business With McCormick, Sources Say -- WSJ

2026. g. 30. marts 21:33 UTC

Iegādes, apvienošanās, pārņemšana

Deal Set to Value Combined Food Business At Around $60B Including Debt, Sources Say -- WSJ

2026. g. 30. marts 21:25 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 30. marts 21:25 UTC

Tirgus saruna

Warehouse Showing Cost Discipline But Margin Goal at Risk -- Market Talk

2026. g. 30. marts 21:03 UTC

Iegādes, apvienošanās, pārņemšana

Sun Life: Completes Equity Interest Purchases of BGO and Crescent Cap, Announces Acquisition of Bell Partners, a Multifamily Real Estate Investment Manager

2026. g. 30. marts 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 30. marts 20:09 UTC

Peļņas

This Stock Looks Like a Solid AI Bet -- and Wall Street Hasn't Noticed Yet -- Barrons.com

2026. g. 30. marts 20:00 UTC

Galvenie ziņu notikumi

Fed's Williams: Middle-East Conflict 'Will Likely Boost Overall Inflation in Coming Months'

Salīdzinājums

Cenas izmaiņa

Ionis Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

34.02% augšup

Prognoze 12 mēnešiem

Vidējais 97.19 USD 34.02%

Augstākais 120 USD

Zemākais 72 USD

Pamatojoties uz 14 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Ionis Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

14 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 14 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Ionis Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

29.78 / 33.645Atbalsts un pretestība

The bullish and bearish events are balanced.

All events are bullish.

All events are bearish.

Noskaņojums

By Acuity

169 / 349 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.